Dual CD40/CD28 co-stimulation reprograms the solid-tumor microenvironment to unleash CAR-T and endogenous anti-tumor immunity
Chimeric antigen receptor (CAR) T-cell therapy has shown limited efficacy against solid tumors, owing to poor T-cell persistence, an immunosuppressive tumo